Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) will host a conference call on May 11, 2021, at 8:30 a.m. ET to discuss its Q1 2021 financial results and recent business highlights. The call will be accessible through a live webcast on the company’s website. Imara is focused on developing therapies for rare genetic disorders affecting hemoglobin, with its lead candidate, IMR-687, targeting conditions such as sickle cell disease and beta-thalassemia. IMR-687 is a potent oral treatment designed to modify disease mechanisms.

Positive

• Imara is advancing IMR-687, a potentially disease-modifying treatment.
• IMR-687 targets sickle cell disease and beta-thalassemia with a multimodal mechanism.

Negative

• None.

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Tuesday, May 11, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2021 and review recent business highlights.

A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 7598753. A replay of the webcast will be archived on the Imara website following the presentation.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Media Contact:
Gina Nugent
Ten Bridge Communications
617-460-3579
gina@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

When will Imara report its Q1 2021 financial results?

Imara will report its Q1 2021 financial results on May 11, 2021, during a conference call.

How can investors listen to Imara's conference call?

Investors can listen to Imara's conference call by dialing 1 (833) 519-1307 or +1 (914) 800-3873 and using conference ID 7598753.

What is the focus of Imara's developmental pipeline?

Imara focuses on developing therapeutics for rare inherited genetic disorders of hemoglobin.

What is IMR-687 intended to treat?

IMR-687 is designed to treat sickle cell disease and beta-thalassemia.

Where can I find the webcast of Imara's conference call?

The webcast of Imara's conference call will be available in the 'Events and Presentations' section of their website.